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Abstract
 
Accumulating evidence indicates that the Cbl protein plays a negative role in immune receptor
 
signaling; however, the mode of Cbl action in B cell receptor (BCR) signaling still remains
unclear. DT40 B cells deficient in Cbl showed enhanced BCR-mediated phospholipase C
 
(PLC)-
 
g
 
2 activation, thereby leading to increased apoptosis. A possible explanation for the in-
volvement of Cbl in PLC-
 
g
 
2 activation was provided by findings that Cbl interacts via its Src
homology 2 (SH2) domain with B cell linker protein (BLNK) after BCR ligation. BLNK is a
critical adaptor molecule for PLC-
 
g
 
2 tyrosine phosphorylation through its binding to the PLC-
 
g
 
2 SH2 domains. As a consequence of the interaction between Cbl and BLNK, the BCR-induced
recruitment of PLC-
 
g
 
2 to BLNK and the subsequent PLC-
 
g
 
2 tyrosine phosphorylation were
inhibited. Thus, our data suggest that Cbl negatively regulates the PLC-
 
g
 
2 pathway by inhibit-
ing the association of PLC-
 
g
 
2 with BLNK.
Key words: adaptor molecule • antigen receptor • lymphocyte • negative regulator • signaling
 
Introduction
 
Cbl is the cellular homologue of the v-Cbl oncoprotein
 
(1), which was originally identified in the murine Cas NS-1
retrovirus (2). v-Cbl induces pre-B cell and myeloid tu-
mors in mice (2), and transforms rodent fibroblasts (3). Re-
cently, Cbl has been identified as a prominent substrate of
 
protein tyrosine kinases (PTKs)
 
1
 
 that is rapidly phosphory-
lated after engagement of several different receptors on he-
matopoietic cells. Cbl has no known catalytic function, but
it contains a RING finger domain, an extensive proline-
rich region, and a COOH-terminal leucine zipper (for re-
views, see references 4–8). Although it has been thought
that Cbl contains a novel NH
 
2
 
-terminal phosphotyrosine-
binding domain (9), recent crystal structure analyses indi-
cate that the Cbl NH
 
2
 
-terminal region (Cbl-N) is not sim-
ilar to a phosphotyrosine-binding domain (10, 11). Instead,
this region comprises three domains: an NH
 
2
 
-terminal
four-helix bundle, a calcium-binding domain, and an un-
usual Src homology 2 (SH2) domain. Moreover, this study
clarifies that G306E mutation in Cbl is located inside its
unusual SH2 domain, and that this mutation disrupts bind-
ing of Cbl to phosphotyrosine-containing proteins (10).
The functional importance of Cbl in hematopoietic cell
signaling was initially suggested by the finding that Cbl
binds to several critical signaling molecules, e.g., PTKs
such as Src family PTK (12–14), Syk/Zap-70 family PTK
(8, 15–18), and Btk (19); adaptor molecules, including
Grb2 (13, 20), Crk (21–23), and Nck (24); and effector
molecules, including phosphatidylinositol 3-kinase (PI3-K
[16, 25]) and Vav (26). The most revealing clue about the
 
function of Cbl came from genetic studies in 
 
Caenorhabditis
elegans
 
, where SLI-1, a 
 
C
 
.
 
 elegans
 
 Cbl homologue, nega-
tively regulates signaling downstream of LET-23, a 
 
C
 
.
 
 ele-
gans
 
 epidermal growth factor receptor homologue (27, 28).
Recent studies have provided evidence that Cbl is involved
in regulating PTKs rather than downstream effectors. In-
deed, overexpression of Cbl in mast cells suppresses Syk
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function upon Fc
 
e
 
RI engagement (29). This is presumably
because of the interaction of the Cbl SH2 domain with the
phosphorylation site in human Syk Tyr-323 (equivalent to
Tyr-316 in porcine Syk), since either inactivation of the
Cbl SH2 domain (G306E mutation) or Syk-Y323F muta-
tion leads to abrogation of Cbl’s negative influence on Syk
in a heterologous COS cell system (30). Moreover, this
study demonstrates the possibility that Cbl targets the auto-
phosphorylated Syk for degradation, leading to downregu-
lation of the expression level of Syk.
Consistent with the negative role of Cbl in Syk function,
Cbl-deficient mouse thymocytes exhibited hyperactivation
of Zap-70 after CD3 cross-linking (31–33). However, con-
trary to the expectation from the hyperactivated Zap-70 in
the Cbl-deficient thymocytes, neither PLC-
 
g
 
1 nor PI3-K
activities were enhanced in these thymocytes (32). Thus, it
is still unclear whether the target molecule of Cbl in anti-
gen receptor signaling is solely a PTK such as Syk/Zap-70.
To address this issue, we have used the DT40 B cell sys-
tem. First, by generating DT40 B cells deficient in Cbl, we
have shown that Cbl negatively regulates the B cell recep-
tor (BCR)-induced PLC-
 
g
 
2 pathway. Given the previous
evidence that BCR-mediated PLC-
 
g
 
2 activation requires
its association with BLNK (alternatively named SH2 do-
main–containing leukocyte protein of 65 kD [SLP-65] or
B cell adaptor containing the SH2 domain [BASH]) (34–
38), as well as two types of PTKs (Syk and Btk; for reviews,
see references 39–42), two models could be put forward to
account for this phenotype. In the first model, Cbl acts on
PTKs, particularly Syk, which in turn inhibits PLC-
 
g
 
2 ty-
rosine phosphorylation. In the second model, Cbl binds to
the phosphorylated BLNK through its SH2 domain, possi-
bly to competitively inhibit the association of the PLC-
 
g
 
2
SH2 domain with BLNK, leading to inhibition of PLC-
 
g
 
2
phosphorylation. Our findings suggest that Cbl dominantly
utilizes the second mechanism in the BCR signaling con-
text.
 
Materials and Methods
 
Cells and Abs. 
 
Wild-type and various mutant chicken DT40
B cells were maintained in RPMI 1640 supplemented with 10%
FCS, 1% chicken serum, 50 
 
m
 
M 
 
b
 
-mercaptoethanol, 2 mM
 
l
 
-glutamine, penicillin, and streptomycin. Anti–PLC-
 
g
 
2 Ab (34),
anti-Syk Ab (43), anti-BLNK Ab (34), and anti–chicken IgM
mAb M4 (44) were described previously. Anti-Cbl Ab and anti–
glutathione 
 
S
 
-transferase (GST) mAb were purchased from Santa
Cruz Biotechnology. Anti-T7 mAb and antiphosphotyrosine
mAb 4G10 were purchased from Novagen and from Upstate
Biotechnology, respectively.
 
Generation of Cbl-deficient DT40 Cells. 
 
Chicken Cbl cDNA
that corresponds to human c-Cbl amino acid residues 77–426 was
isolated by reverse transcriptase PCR using RNA from chicken
DT40 B cells. Cbl genomic DNA fragments were obtained by
screening a chicken genomic library (Clontech Laboratories) us-
ing the isolated chicken Cbl cDNA. The targeting vectors pCbl-
Bsr, pCbl-HisD, pCbl-Puro, and pCbl-Neo were constructed by
replacing the genomic fragment–containing exons that corre-
spond to human c-Cbl amino acids 250–336 with 
 
bsr
 
, 
 
hisD
 
, 
 
puro
 
,
 
or 
 
neo
 
 cassettes. These cassettes were flanked by 3.4 and 6.6 kb of
chicken Cbl genomic sequence on the 5
 
9
 
 and 3
 
9
 
 sides, respec-
tively. The targeting vector pCbl-Bsr was linearized and intro-
duced into wild-type DT40 cells by electroporation at 550 V, 25
 
m
 
F. Transfectants were selected in the presence of 50 
 
m
 
g/ml blas-
ticidin S, and resistant clones were screened by Southern blot
analysis. pCbl-HisD was transfected into the 
 
bsr
 
-targeted clone,
and was selected with both blasticidin S (50 
 
m
 
g/ml) and histidinol
(1 mg/ml). pCbl-Puro was transfected into the 
 
bsr
 
/
 
his
 
-targeted
clone, and was selected with blasticidin S (50 
 
m
 
g/ml), histidinol
(0.5 mg/ml), and puromycin (0.5 
 
m
 
g/ml). pCbl-Neo was trans-
fected into the 
 
bsr
 
/
 
his
 
/
 
puro
 
-targeted clone, and was selected with
blasticidin S (50 
 
m
 
g/ml), histidinol (0.5 mg/ml), puromycin (0.5
 
m
 
g/ml), and G418 (2 mg/ml).
DT40 B cells display a stable karyotype with a modal chromo-
some number of 80, which comprises 11 autosomal macrochro-
mosomes, the ZW sex chromosomes, and 67 microchromo-
somes. The karyotype does not show obvious abnormalities,
except for a trisomy of chromosome 2 and one additional micro-
chromosome (45). The requirement for four rounds of targeting
in generating a null mutant suggested that the DT40 B cell has
two alleles with a duplicated 
 
cbl
 
 gene, although the possibility that
four copies of a 
 
cbl
 
 gene are integrated in a single chromosome,
such as sex chromosomes, could not be excluded.
Although some critical experiments (see Fig. 3) were carried
out using another independent Cbl-deficient clone (C8-12), a
single Cbl-deficient clone (C8-10) was analyzed extensively and
transfected with c-Cbl cDNAs.
 
Expression Constructs. 
 
The hemagglutinin-tagged human c-Cbl
cDNA (provided by Dr. W.Y. Langdon, University of Western
Australia, Nedlands, Australia [1]) was subcloned into the pAzeo
expression vector, which was generated by replacing the CMV
promoter on pcDNA3.1/Zeo (Invitrogen) with the chicken actin
promoter on pApuro (43). Mutation of Gly-306 to Glu, desig-
nated G306E, was introduced into the hemagglutinin-tagged
human c-Cbl cDNA by PCR-directed mutagenesis. Transfection
into Cbl-deficient DT40 cells was done by electroporation at
550 V, 25 
 
m
 
F. Selection was performed in the presence of zeocin
(1 mg/ml). T7-tagged Btk cDNA subcloned into both pApuro
and pAhygro was transfected into wild-type or Cbl-deficient
DT40 cells, respectively. Mutation of porcine Syk Tyr-316 to
Phe (Y316F), which corresponds to human Syk Tyr-323, was
produced by PCR-directed mutagenesis. Wild-type and Syk-Y316F
cDNAs were subcloned into pApuro, and were transfected into
Syk-deficient DT40 cells. Expression of each transfectant was
confirmed by Western blot analysis.
 
Northern Blot Analysis. 
 
RNA was prepared from wild-type
and Cbl-deficient DT40 cells using the guanidium thiocyanate
method. Total RNA (20 
 
m
 
g) was separated in 1.2% formalde-
hyde gel, transferred to Hybond™-N
 
1
 
 membrane (Amersham
Pharmacia Biotech), and probed with 
 
32
 
P-labeled chicken Cbl
cDNA.
 
Immunoprecipitation, Western Blot Analysis, and In Vitro Kinase
Assay. 
 
For immunoprecipitation, cells were solubilized in NP-
40 lysis buffer supplemented with protease and phosphatase in-
hibitors (43), and precleared lysates were sequentially incubated
with proper Abs and protein A-agarose. The immunoprecipitates
were washed four times with lysis buffer. Whole cell lysates were
prepared from unstimulated or M4-stimulated cells using SDS
sample buffer. Whole cell lysates or immunoprecipitates were
separated by SDS-PAGE, transferred to nitrocellulose mem-
branes, and detected by appropriate Abs and the enhanced
chemiluminescence (ECL) system (Amersham Pharmacia Bio- 
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tech). To examine in vitro kinase activity of Syk, immunoprecip-
itated Syk was suspended in kinase buffer (20 mM Tris, pH 7.5,
10 mM MgCl
 
2
 
, 10 mM MnCl
 
2
 
) in the presence of 10 
 
m
 
Ci of
[
 
g
 
-
 
32
 
P]ATP (
 
.
 
3,000 Ci/mmol). Recombinant GST fusion pro-
tein containing a cytoplasmic domain of mouse Ig
 
a
 
 (5 
 
m
 
g) was
used as an exogenous substrate (46). The reactions were allowed
to incubate at 30
 
8
 
C for 10 min. For in vitro kinase assay of Btk,
immunoprecipitated Btk was suspended in kinase buffer (20 mM
Pipes, pH 7.5, 20 mM MnCl
 
2
 
) containing 10 
 
m
 
Ci of [
 
g
 
-
 
32
 
P]ATP
(
 
.
 
3,000 Ci/mmol) and 5 
 
m
 
g of enolase (Sigma Chemical Co.),
and was incubated at 25
 
8
 
C for 3 min. The kinase reactions were
terminated by the addition of SDS sample buffer. The mixtures
were separated by SDS-PAGE gel, followed by autoradiography.
 
Inositol 1,4,5-Trisphosphate Generation Assay. 
 
Cells (2 
 
3
 
 10
 
6
 
)
were stimulated with mAb M4 (2 
 
m
 
g) at 37
 
8
 
C for the indicated
time. Determination of inositol 1,4,5-trisphosphate (IP
 
3
 
) produc-
tion was performed using the Biotrak IP
 
3
 
 assay system (Amer-
sham Pharmacia Biotech) according to the manufacturer’s proto-
col. Results are shown as the mean from three independent
experiments. Error bars represent the SD from the mean.
 
Calcium Measurements. 
 
Cells (5 
 
3
 
 10
 
6
 
) were suspended in
PBS containing 20 mM Hepes (pH 7.2), 5 mM glucose, 0.025%
BSA, and 1 mM CaCl
 
2
 
, and
 
 
 
were loaded with 3 
 
m
 
M acetoxy-
methyl ester of fura-2 (fura-2 AM) at 378C for 45 min. Cells were
washed twice, and were adjusted to 106 cells/ml. Continuous
monitoring of fluorescence from the cell suspension was per-
formed using a fluorescence spectrophotometer (model F-2000;
Hitachi Instruments) at an excitation wavelength of 340 nm and
an emission wavelength of 510 nm. Calibration and calculation of
calcium levels were done as described (47).
Flow Cytometric Analysis.  For DNA content analysis, stimu-
lated or unstimulated cells were pelleted and resuspended in hy-
potonic DNA staining solution (50 mg/ml propidium iodide,
0.1% sodium citrate, 0.1% Triton X-100). Samples were kept at
48C overnight, and were subjected to analysis by FACScan™
(Becton Dickinson). Debris and doublets were excluded by ap-
propriate gating (48). For cell surface expression of BCR, DT40
cells were washed, incubated with FITC-conjugated anti–
chicken IgM (Bethyl Laboratories), and analyzed using FAC-
Scan™. The x and y axes for the histograms indicate fluorescence
intensity (four-decade log scales) and relative cell number, re-
spectively.
Binding Assay with GST Fusion Proteins.  Human Cbl sequences
encoding amino acids 25–351 were amplified by PCR from
wild-type or G306E Cbl cDNAs, and were cloned as BamHI-
XhoI fragments into the pGEX-4T-1 vector (Amersham Phar-
macia Biotech). GST fusion proteins were affinity purified by
glutathione-Sepharose beads (Amersham Pharmacia Biotech).
For in vitro binding assays, stimulated or unstimulated DT40 cell
lysates (1 3 107) were incubated with 20 mg of purified GST fu-
sion proteins for 1 h at 48C. The binding mixtures were washed
extensively in NP-40 lysis buffer. Bound proteins or whole cell
lysates were resolved by SDS-PAGE, transferred to nitrocellulose
membranes, and detected by anti-BLNK Ab and ECL. For far-
Western blotting, anti-BLNK immunoprecipitates were sepa-
rated on a 7% SDS-PAGE gel and then transferred to polyvi-
nylidene difluoride membranes. The blotted membranes were
incubated with 2.5 mg/ml eluted GST fusion proteins, and were
detected using anti-GST mAb and ECL.
Results
Cbl Negatively Regulates the PLC-g2 Pathway.  To disrupt
the  cbl locus in DT40 B cells, we transfected a targeting
construct pCbl-Bsr into parental DT40 B cells. Southern
blot analysis indicated that 10 out of 24 blasticidin-resistant
clones had sustained a targeting event (data not shown).
The hybridization signal of a rearranged 5.4-kb band was
two- or threefold weaker than the wild-type 4.9-kb band,
suggesting that DT40 cells contain more than two alleles of
the cbl locus (Fig. 1 A). Disruption of the remaining alleles
of the cbl locus was accompanied by the sequential transfec-
Figure 1. Disruption of the cbl gene in chicken DT40 B cells. (A)
Southern blot analysis of wild-type and various targeted DT40 cells. Hind-
III-digested genomic DNA separated on agarose gel was blotted and hy-
bridized with a chicken Cbl cDNA probe. Wild-type (wt) and bsr-, hisD-,
puro-, and neo-targeted alleles showed 4.9-, 5.4-, 7.4-, 5.4-, or 7.9-kb
fragments, respectively. (B) Northern blot analysis using a chicken cDNA
probe for Cbl (top) or b-actin (bottom). The position of 28 S rRNA is
indicated. (C) Protein expression analysis of Cbl in wild-type (wt) and
Cbl-deficient (cbl2) DT40 cells. Total cell lysates (2 3 106 cells) were pre-
pared and analyzed by Western blotting using anti-Cbl Ab.
Figure 2. Cell surface expression of BCR. BCR expression on the sur-
face of wild-type (wt), Cbl-deficient (cbl2), and various mutant DT40
cells was determined by flow cytometry. Unstained cells were used as
negative controls (filled histogram). Syk-deficient cells expressing wild-
type and Y316F mutant of Syk are indicated as wtSyk and Y316FSyk, re-
spectively. Cbl-deficient cells (C8-10) expressing wild-type Cbl and its
G306E mutant are shown as wtCbl and G306ECbl, respectively.644 Function of Cbl in BCR Signaling
tion of three other targeting constructs, pCbl-HisD, pCbl-
Puro, and pCbl-Neo (Fig. 1 A). Hybridization with a bsr,
hisD, puro, or neo probe indicated that the targeted clone
had incorporated a single copy of each construct (data not
shown). Lack of Cbl was verified by Northern and Western
analyses (Fig. 1, B and C). The level of cell surface expres-
sion of BCR on the targeted DT40 cells was the same as
that of parental cells (Fig. 2).
One of the hallmarks of BCR-induced signaling is cal-
cium mobilization. Fura-2–loaded wild-type and Cbl-defi-
cient (C8-10) DT40 cells were stimulated with anti-BCR
mAb M4, and the rise of intracellular Ca21 ([Ca21]i) was
measured. As shown in Fig. 3 A, the peak height of the
[Ca21]i increase upon receptor stimulation was enhanced
by z1.3-fold by loss of Cbl. Because IP3 generation medi-
ated by PLC-g2 is primarily important for BCR-induced
calcium mobilization through its binding to IP3 receptors,
BCR-induced IP3 generation in wild-type and Cbl-defi-
cient B cells was examined. Cbl-deficient cells exhibited
increased IP3 generation compared with wild-type cells;
the peak stimulation after BCR ligation was threefold more
than wild-type DT40 cells (Fig. 3 B). We also examined
another independent Cbl-deficient clone (C8-12), which
indicated essentially the same abnormalities as clone C8-10.
Furthermore, transfection of wild-type Cbl cDNA into
clone C8-10 restored normal BCR-mediated calcium mo-
bilization (Fig. 3 A), as well as IP3 generation (see Fig. 8 B).
Based on these data, we conclude that Cbl negatively regu-
lates PLC-g2 activation after BCR stimulation.
BCR-mediated Apoptosis Is Enhanced in Cbl-deficient DT40
Cells.  As PLC-g2 activation is required for BCR-induced
apoptosis in DT40 B cells (49), we reasoned that the recep-
tor-induced apoptosis might be augmented by the en-
hanced PLC-g2 activation in Cbl-deficient DT40 cells. As
shown in Fig. 4, the BCR-induced apoptosis was clearly
enhanced by loss of Cbl, demonstrating that Cbl negatively
regulates BCR-mediated apoptosis through the PLC-g2
pathway.
Enhancement of BCR-induced Tyrosine Phosphorylation of
PLC-g2 by Loss of Cbl.  To explore the mechanism by
which Cbl mediates its inhibitory effect on PLC-g2 activa-
tion, the BCR-mediated tyrosine phosphorylation status of
PLC-g2 was determined in wild-type and Cbl-deficient
cells. Compared with wild-type cells, PLC-g2 tyrosine
phosphorylation in Cbl-deficient DT40 B cells was increased
by about three- to fivefold, as assessed by antiphosphoty-
rosine mAb blotting analysis (Fig. 3 C). These observations
indicate that PLC-g2 hyperactivation in Cbl-deficient DT40
cells is most likely due to the enhanced tyrosine phosphory-
lation of PLC-g2 in the BCR signaling context.
As Syk and Btk are the PTKs responsible for BCR-
induced PLC-g2 tyrosine phosphorylation (43, 50), one pos-
sible explanation for the enhanced PLC-g2 phosphoryla-
tion in Cbl-deficient cells is that Syk and/or Btk are
Figure 3. Characterization of Cbl-deficient DT40 cells. (A) Calcium
mobilization in wild-type (wt) DT40 cells, Cbl-deficient clones (C8-10
and C8-12), and C8-10 clone expressing wild-type Cbl (see Fig. 8).
[Ca21]i levels were monitored by a spectrophotometer after stimulation
with M4 (2 mg/ml). Arrows indicate the time point for adding M4. (B)
IP3 generation. Cells were stimulated with M4 for the indicated amount
of time, and IP3 production was measured. (C) Tyrosine phosphorylation
of PLC-g2. At the indicated time points after the M4 stimulation (4 mg/
ml), immunoprecipitates with anti–PLC-g2 Ab were separated on a 7%
SDS-PAGE gel, and were analyzed by Western blotting with antiphos-
photyrosine mAb (top, anti-pY) or anti–PLC-g2 Ab (bottom).
Figure 4. Induction of apoptosis in wild-type and Cbl-deficient DT40
cells. Wild-type (wt) and Cbl-deficient (C8-10, cbl2) DT40 cells were
cultured with (1) or without (2) M4 (10 mg/ml, 24 h), treated in hypo-
tonic DNA staining solution containing 50 mg/ml propidium iodide, and
subjected to analysis by FACScan™ (Becton Dickinson). The percentage
of fragmented nuclei is indicated.645 Yasuda et al.
hyperactivated in Cbl-deficient DT40 cells, leading to hy-
perphosphorylation of PLC-g2. To evaluate this possibil-
ity, the BCR-induced whole tyrosine phosphorylation pat-
tern was compared in wild-type and mutant cells. As
shown in Fig. 5 A, there were no significant changes be-
tween wild-type and Cbl-deficient cells, except that the
band corresponding to Cbl itself was absent in the mutant
cells. Consistent with the whole tyrosine phosphorylation
data, both Syk and Btk were inducibly tyrosine phosphory-
lated to an almost similar extent in wild-type and Cbl-defi-
cient DT40 cells. In addition, the BCR-induced in vitro
kinase activities of Syk and Btk were almost the same be-
tween wild-type and mutant DT40 cells (Fig. 5, B and C).
Previous overexpression experiments using the COS cell
system have indicated that a potential target of the Cbl SH2
domain is phosphorylated tyrosine 316 of porcine Syk (30).
To formally demonstrate that PLC-g2 hyperactivation by
loss of Cbl cannot be accounted for by the interaction be-
tween Cbl and Syk, we determined the effect of the Syk-
Y316F mutation on BCR-mediated PLC-g2 activation.
Wild-type Syk and its mutant (Y316F) were transfected
into Syk-deficient DT40 cells, and the resulting DT40
clones expressing similar levels of Syk were characterized
(Fig. 6 A). As shown in Fig. 6 (B and C), BCR-mediated
tyrosine phosphorylation of PLC-g2 and subsequent IP3
production were only marginally enhanced by this muta-
tion. Together, these results demonstrate that activation of
Syk and Btk is not significantly perturbed by loss of Cbl.
Recruitment of PLC-g2 to BLNK Is Significantly Enhanced
in Cbl-deficient B Cells.  The adaptor molecule BLNK is
shown to be essential for BCR-mediated tyrosine phos-
phorylation of PLC-g2, in that phosphorylated BLNK pro-
vides docking sites for PLC-g2 SH2 domains, leading to
recruitment of PLC-g2 into the close proximity of Btk and
Syk (36). Thus, the effect of disruption of Cbl on associa-
tion of PLC-g2 to BLNK after BCR ligation was exam-
ined. As this association is SH2–phosphotyrosine depen-
dent, we first checked the tyrosine phosphorylation status
of BLNK (Fig. 7 A), which indicated the same level be-
tween wild-type and Cbl-deficient DT40 cells. Despite the
same level of BLNK phosphorylation, BCR-induced asso-
ciation of PLC-g2 with BLNK was significantly aug-
mented by loss of Cbl (Fig. 7 B). Given that the extent of
PLC-g2 association to BLNK correlates well with the
phosphorylation extent of PLC-g2 (36), the enhanced as-
sociation between PLC-g2 and BLNK in Cbl-deficient
cells is likely to cause hyperphosphorylation of PLC-g2.
Figure 5. BCR-induced tyrosine phosphorylation in
wild-type and Cbl-deficient DT40 cells. C8-10 was used
for a Cbl-deficient clone. (A) Tyrosine phosphorylation
in whole cell lysates from wild-type (wt) and Cbl-defi-
cient (cbl2) DT40 cells. At the indicated time points after
addition of M4 (4 mg/ml), whole cell lysates prepared
from 2 3 106 cells were loaded onto an 8% SDS-PAGE
gel. The blotted membrane was incubated with an-
tiphosphotyrosine Ab. (B) Tyrosine phosphorylation and
in vitro kinase activity of Syk. Wild-type and Cbl-defi-
cient DT40 cells were stimulated with M4 for the indi-
cated amount of time, and were immunoprecipitated
with anti-Syk Ab. Immunoprecipitates were divided, and
one third was used for Western blotting with antiphos-
photyrosine mAb (top, anti-pY) or anti-Syk Ab (bot-
tom). The remaining third was used for the in vitro ki-
nase assay (middle). (C) Tyrosine phosphorylation and in
vitro kinase activity of Btk. Wild-type and Cbl-deficient
DT40 cells expressing T7-tagged Btk were stimulated
with M4 for the indicated amount of time, and were im-
munoprecipitated with anti-T7 mAb. Immunoprecipi-
tates were divided, and one third was used for Western
blotting with antiphosphotyrosine mAb (top) or anti-T7
mAb (bottom). The remaining third was used for the in
vitro kinase assay (middle).
Figure 6. Effect of Syk-
Y316F mutation on PLC-g2 ac-
tivation. Syk-deficient DT40
cells that stably expressed wild-
type or Syk-Y316F were analyzed.
(A) Expression of wild-type or
Syk-Y316F in Syk-deficient
cells. Total cell lysates (2 3 106
cells) were prepared and ana-
lyzed by Western blotting using
anti-Syk Ab. (B) BCR-induced
IP3 generation and (C) tyrosine
phosphorylation of PLC-g2
were examined as described in
the legend to Fig. 3.646 Function of Cbl in BCR Signaling
Association of Cbl with BLNK Is Dependent on the Cbl SH2
Domain.  The above observations suggest that Cbl acts
through its SH2 domain to competitively inhibit the asso-
ciation between PLC-g2 and BLNK. To verify this possi-
bility, the effect of the Cbl SH2 mutant (G306E) on BCR-
mediated PLC-g2 activation was determined. Wild-type
Cbl and its SH2 mutant (G306E) were transfected into the
Cbl-deficient DT40 clone (C8-10), and DT40 clones ex-
pressing similar expression levels of Cbl, as assessed by im-
munoblotting analysis (Fig. 8 A), were selected and further
characterized. Wild-type Cbl reverted both PLC-g2 ty-
rosine phosphorylation and IP3 generation upon BCR
cross-linking, whereas the SH2 mutant could not, demon-
strating the importance of the SH2 domain in Cbl’s nega-
tive influence on PLC-g2 activation (Fig. 8, B and C).
Moreover, recruitment of Cbl to phosphorylated BLNK
was dependent on the Cbl SH2 domain (Fig. 8 D).
To further examine the ability of the Cbl SH2 domain
to bind to phosphorylated BLNK in vitro, we used GST
fusion protein containing the Cbl-N. Binding of GST–
Cbl-N to BLNK in lysates of unstimulated DT40 cells was
low, but it increased substantially upon BCR stimulation.
Importantly, G306E mutation in Cbl-N completely abro-
gated binding to phosphorylated BLNK (Fig. 9 A). These
results establish that the Cbl SH2 domain interacts with
phosphorylated BLNK in a lysate binding assay. However,
it is possible that this interaction is indirectly mediated by
an adaptor molecule. To determine if the Cbl SH2 domain
directly binds to phosphorylated BLNK, a far-Western
blotting was performed. As seen in Fig. 9 B, GST–Cbl-N
Figure 7. BCR-induced association
of PLC-g2 to BLNK. (A) Tyrosine
phosphorylation of BLNK. Wild-type
(wt) or Cbl-deficient (C8-10, cbl2)
DT40 cells (5 3 106) were lysed at the
indicated time points after M4 stimula-
tion (4 mg/ml), and immunoprecipitates
with anti-BLNK Ab were separated on
an 8% SDS-PAGE gel and blotted with
antiphosphotyrosine mAb (top, anti-pY)
or anti-BLNK Ab (bottom). (B) Interac-
tion of PLC-g2 with BLNK. PLC-g2
was immunoprecipitated from wild-type
or Cbl-deficient (C8-10) DT40 cells
(5  3 107) before (2) or after (1) stimu-
lation (sti) with M4 (4 mg/ml) for 1 min,
and immunoprecipitates were separated
on a 7% SDS-PAGE gel. The blotted
membrane was incubated with anti-
BLNK Ab (top) or anti–PLC-g2 Ab
(bottom).
Figure 8. Effect of mutation in the Cbl SH2 domain on PLC-g2 acti-
vation. Cbl-deficient DT40 cells that stably expressed wild-type or
G306E Cbl were analyzed. (A) Expression of wild-type or G306E Cbl in
Cbl-deficient cells (C8-10). Total cell lysates (2 3 106 cells) were pre-
pared and analyzed by Western blotting using anti-Cbl Ab. (B) BCR-
induced IP3 generation and (C) tyrosine phosphorylation of PLC-g2
were examined as described in the legend to Fig. 3. (D) Recruitment of
Cbl to BLNK. BLNK was immunoprecipitated from 5 3 107 cells before
(2) or after (1) stimulation (sti) with M4 (4 mg/ml) for 1 min, and im-
munoprecipitates were separated on a 7% SDS-PAGE gel. The blotted
membrane was incubated with anti-Cbl Ab (top), antiphosphotyrosine
mAb (middle, anti-pY), or anti-BLNK Ab (bottom). Phosphorylated
BLNK is shown in the middle panel.
Figure 9. Direct binding of Cbl-N to BLNK. (A) In vitro binding of
the Cbl-N with BLNK. DT40 cells unstimulated (2) or stimulated (1)
with M4 (4 mg/ml) for 1 min were lysed, and were incubated with GST
or the indicated GST–Cbl-N fusion proteins. The precipitates (top) or
whole cell lysates (middle) were separated on a 7% SDS-PAGE gel and
immunoblotted with anti-BLNK Ab. GST fusion proteins used in precip-
itation were visualized by Coomassie staining (bottom). (B) For far-West-
ern blotting, wild-type (wt) or BLNK-deficient (BLNK2) DT40 cells (5 3
107) were stimulated for 1 min with M4 (4 mg/ml), lysed, and immuno-
precipitated with anti-BLNK Ab. Immunoprecipitates were divided, and
half were separated on a 7% SDS-PAGE gel, transferred to polyvinylidene
difluoride membranes, incubated with the indicated soluble GST fusion
proteins, and detected using anti-GST mAb (top). The remaining half
were used for Western blotting with anti-BLNK Ab (bottom).647 Yasuda et al.
directly bound to phosphorylated BLNK; in contrast, no
binding was observed with GST or GST–Cbl-N (G306E).
These data demonstrate that the Cbl SH2 domain can di-
rectly bind to phosphorylated BLNK.
Discussion
In this study, we have addressed three questions regard-
ing the function of Cbl: (a) does Cbl function as a negative
regulator in BCR signaling, as well as in the case of TCR
or FceRI (29, 31, 33); (b) if so, which signaling pathway(s)
is a physiological target of Cbl in the BCR signaling con-
text; and (c) what is the molecular mechanism by which
Cbl influences the BCR signaling pathway?
DT40 B cells deficient in Cbl exhibited hyperactivation
of PLC-g2 (Fig. 3) and hyperapoptosis (Fig. 4) in response
to BCR ligation, supporting the previous contention that
Cbl functions as a negative regulator in immune receptor
signaling. Since the previous evidence has shown that
BCR-mediated apoptosis in DT40 B cells requires the
PLC-g2 pathway (49), BCR-mediated hyperapoptosis in
Cbl-deficient DT40 cells is most likely accounted for by
hyperactivation of the PLC-g2 pathway. In contrast to
threefold enhancement of IP3 production in Cbl-deficient
cells compared with wild-type DT40, the BCR-mediated
calcium mobilization was increased by z1.3-fold by loss of
Cbl, suggesting that the molecule(s) lying between PLC-g2
activation and calcium mobilization, such as IP3 receptors,
may have a limiting factor for transmission from IP3 gener-
ation to calcium mobilization in the DT40 B cell system.
Indeed, we observed previously that the expression level of
PLC-g2 in DT40 cells correlated well with BCR-mediated
IP3 production, whereas calcium mobilization was not lin-
early correlated (49).
It has been shown recently that Cbl regulates ubiquitin-
ation of receptor-type PTKs, such as platelet-derived
growth factor receptor, in a manner dependent on its SH2
and RING finger domains (51–55). Indeed, Cbl has the ca-
pacity to act as a component of ubiquitin–protein ligases
(E3s [54]). The expression levels of TCR components in
Cbl-deficient thymocytes are higher than in wild-type
mice (31–33); in contrast, the expression level of BCR in
Cbl-deficient DT40 cells is not significantly upregulated
(Fig. 2). Thus, one explanation for the functional difference
of Cbl in TCR versus BCR signaling may be that targeting
signals for degradation by Cbl are comprised in CD3 z
chain components, but not BCR Iga/Igb subunits. Cbl-b,
another Cbl-related molecule, is expressed in hematopoie-
tic cells, and the NH2-terminal half of Cbl-b, including
SH2 and RING finger domains, is highly homologous to
Cbl (56). These structural characteristics of Cbl-b suggest
that Cbl-b plays a redundant role in ubiquitin-mediated
degradation. Thus, it is also possible that relatively high ex-
pression of Cbl-b in B cells compared with T cells (57) may
compensate for the degradation function of Cbl in B cells.
Given that phosphatidylinositol 3,4,5-trisphosphate, a
product of PI3-K, participates in positive modulation of
PLC-g activation (58–60), one possible explanation for hy-
peractivation of PLC-g2 in Cbl-deficient DT40 cells is that
the PI3-K pathway is hyperactivated, leading to enhance-
ment of PLC-g2 activation. However, the observations
that BCR-mediated Akt activation, a readout of the PI3-K
pathway, was not affected in Cbl-deficient DT40 cells (data
not shown) suggest that this hyperactivation of PLC-g2 is
mediated through a PI3-K–independent mechanism.
Recent experiments have demonstrated that the adaptor
molecule BLNK, in addition to Syk and Btk, is required
for tyrosine phosphorylation of PLC-g2 and its subsequent
activation (34). Indeed, the phosphorylated BLNK by Syk
provides docking sites for PLC-g2 SH2 domains and its
subsequent phosphorylation (36, 61). Thus, one possible
explanation for the hyperphosphorylation of PLC-g2 by
loss of Cbl is that Cbl negatively regulates Syk function, as
proposed previously in mast cell and COS cell systems (29,
30). However, this possibility is unlikely in the DT40 B
cell system based on the following data: (a) overall tyrosine
phosphorylation was almost the same between wild-type
and Cbl-deficient DT40 cells; (b) a Syk substrate, BLNK,
was normally phosphorylated in Cbl-deficient DT40 cells;
and (c) although the Cbl SH2 domain was essential for ex-
erting Cbl’s negative effect on PLC-g2 phosphorylation,
Syk-Y316F (disruption mutant for binding to the Cbl SH2
domain) did not exhibit significant enhancement of PLC-
g2 phosphorylation, as observed in Cbl-deficient cells.
BCR-mediated Btk activation, as in the case of Syk, oc-
curred normally in Cbl-deficient DT40 B cells. The
present results differ from previous studies using a trans-
fected rat basophilic leukemia mast cell system, which sug-
gested that Cbl directly inhibits the enzymatic activity of
Syk (29). It is possible that when Syk and Cbl proteins are
overexpressed using the vaccinia virus system in rat baso-
philic leukemia cells, SH2-independent binding of Cbl to
Syk could be promoted, thereby leading to a direct nega-
tive impact on Syk enzymatic activity. Another potential
mechanism, enhanced degradation of Syk by Cbl, was pro-
posed based on overexpression experiments in COS cells
(30). The degradation effect of Cbl on Syk may be depen-
dent on the expression level of the activated Syk; overex-
pressed Syk could be more susceptible to degradation.
Thus, it is possible that the effect of Cbl on the endogenous
expression level of Syk in DT40 cells may be too subtle to
be detected by our assay system.
Despite the same levels of BLNK tyrosine phosphoryla-
tion in wild-type and Cbl-deficient DT40 cells, association
of PLC-g2 with BLNK was increased by about threefold in
Cbl-deficient cells, indicating that Cbl negatively modu-
lates the PLC-g2–BLNK association. Since the Cbl SH2
domain was also recruited to phosphorylated BLNK after
BCR ligation (Fig. 8 D and Fig. 9), it would be reasonable
to anticipate that the Cbl SH2 domain and the PLC-g2
SH2 domains are competitively recruited to the phosphor-
ylated BLNK. This idea is further supported by the re-
ported preferred sequences of these SH2 domains. A phos-
phopeptide library screen with the Cbl NH2-terminal
region demonstrated that the binding motif for this region
could be D(N/D)XpY (9). Indeed, chicken BLNK com-648 Function of Cbl in BCR Signaling
prises this binding motif (DDSY115), and this motif is well
conserved in both human and mouse BLNK (34). Interest-
ingly, the sequences that match well the motif selected by
the COOH-terminal SH2 domain of PLC-g2 (Y103VVP
and Y194IVP) are found near this Cbl binding motif (62).
Thus, our biochemical data, together with previous evi-
dence that the extent of BLNK–PLC-g2 association corre-
lates with the level of BCR-mediated PLC-g2 tyrosine
phosphorylation (36), suggest that enhanced BLNK–PLC-
g2 association by loss of Cbl competition causes increased
PLC-g2 phosphorylation, leading to its hyperactivation.
Additional studies are underway to define exactly the in
vivo phosphorylation sites on BLNK for binding to the
PLC-g2 SH2 domains and the Cbl SH2 domain, and to
examine the functional consequences of phosphorylation
on these sites. The importance of the Cbl SH2 domain in
TCR signaling has been suggested by recent results that
TCR-mediated nuclear factor of activated T cells modula-
tion by oncogenic Cbl mutant 70Z was abolished by its
SH2 mutation (63, 64). As nuclear factor of activated T cells
activation is dependent on both PKC activation and calcium
mobilization, this notion is further supported by our findings
that the Cbl SH2 domain is essential for its influence on
BCR-mediated PLC-g2 activation. Although a D(N/D)
XpY motif in Zap-70 (Y292) and Syk (Y316) binds to the
Cbl SH2 domain (9, 10, 30, 65), recent studies indicate that
this interaction cannot fully account for the effect of the Cbl
SH2 domain in immune cells (64, 66, 67). Thus, our identi-
fication here of BLNK as a target of the Cbl SH2 domain
provides another potential mode of Cbl action.
In contrast to the thymic T cell changes in Cbl-deficient
mice, the B cell development in bone marrow appears to
be normal, suggesting differential requirements for Cbl in
T and B cell development (31). Developmental changes in
T cells might reflect the fact that Cbl downregulates the
expression levels of TCR components. In support of this
idea, the BCR expression level in Cbl-deficient mice seems
to be normal (31). Despite no apparent B cell developmen-
tal changes, the peripheral lymph nodes of Cbl-deficient
mice demonstrated increases in both B and T cells (31).
This observation suggests that Cbl functions as a negative
regulator in peripheral B and T cells. Thus, our finding that
Cbl is a negative regulator in the BCR-mediated PLC-g2
pathway may reflect the status of murine peripheral B cells
rather than developing B cells. Comparative studies using
Cbl-deficient mice will be needed to test this hypothesis.
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